FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new purine derivatives of formula (I) and to their pharmaceutically acceptable salts exhibiting the properties of adenosine receptor A2A agonists. The compounds can find application for preparing a drug for treating an inflammatory or obstructive respiratory disease. In formula
,
R1, R2 and R3 are those as specified in the patent claim.
EFFECT: preparing new purine derivatives of formula (I) or their pharmaceutically acceptable salts showing the properties of adenosine receptor A2A agonists.
8 cl, 2 tbl, 264 ex
Title | Year | Author | Number |
---|---|---|---|
MELANOCORTIN-4 RECEPTOR AGONISTS | 2020 |
|
RU2786864C1 |
ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2824528C2 |
2,6-DIAMINOPURINE--β--D-RIBOFURANURONAMIDE DERIVATIVES, METHOD OF PREPARING THEREOF, PHARMACEUTICAL COMPOSITION FOR SUPPRESSING ACTIVITY OF LEUKOCYTES, METHOD OF PREPARING PHARMACEUTICAL COMPOSITION, AND METHOD OF SUPPRESSING LEUKOCYTES | 1994 |
|
RU2129561C1 |
C-6 MODIFIED INDAZOLYL PYRROLOTRIAZINES | 2003 |
|
RU2356903C2 |
ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF PAH | 2020 |
|
RU2786588C1 |
PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2661896C2 |
CASPASE INHIBITORS AND USE THEREOF | 2005 |
|
RU2382780C2 |
CD73 INHIBITOR, ITS PRODUCTION METHOD AND ITS USE | 2020 |
|
RU2787428C1 |
FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2014 |
|
RU2704112C2 |
DERIVATIVES OF 1,3,5-TRIAZINE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND THEIR USING | 2003 |
|
RU2312859C2 |
Authors
Dates
2012-07-27—Published
2007-04-19—Filed